Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib in Localized Ocular Melanoma
NCT05907954Phase 2Active, not recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Jul 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of darovasertib in Uveal melanoma (UM), sponsored by IDEAYA Biosciences. Started Jul 2023; status: active, not recruiting.
02
Drugs
darovasertib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05907954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907954.